TuberculosisPhase 1NCT01574638
Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults
A Phase 1 study testing Rifapentine (RPT) in people with Tuberculosis, run by National Institute of Allergy and Infectious Diseases (NIAID) at 4 sites in United States.
Trial summary
This study will evaluate two different ways to give rifapentine (RPT), a drug that may help shorten treatment duration for tuberculosis (TB) disease. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Tuberculosis
- What is being tested?
- Rifapentine (RPT)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 44 participants
- Where
- 4 sitesUnited States
- Study dates
- Jun 2012to Jun 2013
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Weight of 50 to 100 kg, inclusive
- Absence of HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit within 21 days prior to study entry. NOTE: The term "licensed" refers to a U.S. FDA-approved kit.
- Females of reproductive potential (defined as women who have not been postmenopausal for at least 24 consecutive months, i.e., who have had menses within the preceding 24 months, and do not have documentation of having undergone a sterilization procedure [e.g., hysterectomy or bilateral oophorectomy or salpingectomy]) must have a negative serum or urine beta-human choriogonadotropin (β-HCG) pregnancy test performed within 48 hours prior to entry. The urine test must have a sensitivity of at least 25 mlU/mL and be performed at a laboratory with Clinical Laboratory Improvement Amendment (CLIA) certification or its equivalent.
- If participating in sexual activity that could lead to pregnancy, females must agree to use at least one reliable form of contraceptive while receiving the protocol-specified medications and for 1 week after stopping study medications. At least one (but preferably two) of the following contraceptives MUST be used appropriately:
- Condoms (male or female) with or without a spermicidal agent
- Diaphragm or cervical cap with spermicide
Show all 18Show fewer
- Intrauterine device (IUD)
- NOTE: Hormone-based contraceptives are contraindicated with RPT and therefore may not be used as a form of contraception during this study.
- Ability and willingness of volunteer to provide written informed consent
- Laboratory values obtained within 21 days prior to entry:
- Serum alanine aminotransferase (ALT) less than or equal to 1.2 times the upper limit of normal (ULN)
- Total bilirubin level less than or equal to 1.2 times the ULN
- Serum creatinine less than or equal to 1.5 mg/dL
- Hemoglobin greater than or equal to 12.0 g/dL for men, greater than or equal to 11.0 g/dL for women
- Platelet count greater than or equal to 125,000/mm^3
- Absolute neutrophil count greater than or equal to 1,250/mm^3
- Serum albumin greater than or equal to 3.5 g/dL
- Hepatitis C antibody negative
Who cannot join
- Breastfeeding
- Within 30 days prior to entry, use of any prescription medication known to inhibit or induce cytochrome P (CYP)3A metabolizing enzymes (refer to the manufacturers' package inserts for individual drugs). See list posted on the A5311 protocol-specific webpage (PSWP).
- Known intolerance of or allergy to chicken eggs
- Use of rifamycin antibiotics within 60 days prior to entry
- Planned use during the study of prescription medications, herbal supplements, nutritional supplements, or over-the-counter medications except as follows: multivitamins, acetaminophen (up to 650 mg every 6 hours as an analgesic), ibuprofen (up to 600 mg twice daily), naproxen (up to 500 mg twice daily for pain or headache), and Benadryl (diphenhydramine, up to 25 mg daily for insomnia or seasonal allergies) are permitted. The use of topical or locally-acting drugs (e.g., eye drops, IUDs, skin ointments) will be considered on a case-by-case basis.
- Within 14 days prior to study entry, hospitalization for any reason or pharmacotherapy for serious illness
Show all 16Show fewer
- Within 14 days prior to study entry, use of any prescription medication(s)
- Receipt of any investigational study drug within 21 days prior to study entry
- Known allergy/sensitivity or any hypersensitivity to rifamycins, including rifampin, rifabutin, and rifapentine
- Presence of any condition interfering with normal gastrointestinal anatomy or motility that could interfere with drug absorption or excretion (including cholecystectomy, peptic ulceration, inflammatory bowel disease, or pancreatitis)
- History or evidence of clinically significant (as determined by site investigator) cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric, endocrine, or immunologic disease(s)
- Any medical condition that, in the opinion of the site investigator, would interfere with the participant's ability to participate in the study
- Active illicit drug use or dependence or alcohol dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
- History of TB infection or site investigator suspicion of current active TB
- Inability to abstain from grapefruit and grapefruit juice for the duration of the study
- Inability to adhere to the dietary requirements of the study (e.g., low-fat meal or boiled egg prior to drug doses during the study drug administration periods)
Trial locations and contacts
4 sites in 1 country.
United States4 sites
Johns Hopkins University CRS
Baltimore, Maryland, 21205
Chapel Hill CRS
Chapel Hill, North Carolina, 27599
Vanderbilt Therapeutics (VT) CRS
Nashville, Tennessee, 37204
UCSD Antiviral Research Center CRS
San Diego, California, 92103
About this study
Official title: Phase I Clinical Trial of the Pharmacokinetics of High-dose Daily Rifapentine, Given as a Single Dose or in Divided Doses to Healthy Volunteers
This study will evaluate two different ways to give rifapentine (RPT), a drug that may help shorten treatment duration for tuberculosis (TB) disease.
Read the detailed description
TB continues to be a major global health problem, with an estimated 9.4 million new cases and 1.3 million deaths from TB in 2009. Effective treatment is available, but the current standard therapy consists of 4 different drugs that must be given for 6 months to be effective. RPT is a rifamycin antibiotic approved by the Food and Drug Administration (FDA) to be given twice weekly during the intensive phase of TB treatment and once weekly during the continuation phase of TB treatment. However, studies using this regimen have seen high relapse rates of TB; use of higher and/or more frequent doses may be necessary to attain higher cure rates. This study will evaluate 2 strategies for optimizing RPT exposure: dividing the daily dose in order to increase absorption/overall drug exposure and providing the dose together with food.
Participants will be randomly assigned to one of 4 arms: Arm 1A, Arm 1B, Arm 2A, or Arm 2B. The first 12 participants who indicate that they are willing to remain on the study for up to 12 weeks will be assigned to Arm 2A; all others will be randomized to Arm 1A, 1B, or 2B. Participants in all arms will receive daily RPT from Day 1 to 14, followed by a washout period from Day 15 to 42 during which no RPT will be given, followed by a second period of daily RPT from Day 43 to 56 (and continuing through Day 70 for participants in Arm 2A). Arms 1A and 2B will evaluate twice-daily versus once-daily RPT taken with low-fat meals; Arms 2A and 2B will evaluate once-daily RPT given with an egg versus with a low-fat breakfast.
Total study duration will range from 63 to 70 days for Arms 1A, 1B, and 2B, with 10 study visits: 4 intensive pharmacokinetic (PK) sampling visits (at Days 0 to 2, 13 to 15, 42 to 44, and 55 to 57) and 6 other visits at screening and Days 7, 21, 35, and 49, with the final visit between Days 63 and 70. Total study duration for Arm 2A will range from 77 to 84 days, with 12 study visits: 5 intensive PK sampling visits (over Days 0 to 2, 13 to 15, 42 to 44, 55 to 57, and 69 to 71) and 7 other visits at screening and Days 7, 21, 35, 49, and 64, with the final visit between Days 77 and 84. Intensive PK visits will require the participant to be admitted to the clinic for 1 or 2 nights and to have blood collected multiple times. Interim study visits may consist of giving a medical history, undergoing a physical exam and blood collection, and undergoing a pregnancy test for women of reproductive potential. Participants also will be required to keep a diary of the times they took outpatient study drugs, any medications taken other than the study drug, and any symptoms experienced.
- Conditions
- Tuberculosis
- Being tested
- Rifapentine (RPT)
- Medical subject headings
- Tuberculosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Rifapentine (RPT)Drug
Participants will receive 150-mg RPT tablets orally either once or twice daily, with total tablet number/dosage amount varying according to weight at entry and arm assignment and following dosing tables in the protocol.
| Study group | Role | What they receive |
|---|---|---|
| Arm 1B | Experimental | Participants in Arm 1B will receive RPT based on weight at entry, at a dose of 20 mg/kg once daily with a low-fat breakfast, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 10 mg/kg twice daily with low-fat meals. Receives: Drug: Rifapentine (RPT) |
| Arm 1A | Experimental | Participants in Arm 1A will receive RPT based on weight at entry, at a dose of 10 mg/kg twice daily with low-fat meals, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 20 mg/kg once daily with a low-fat breakfast. Receives: Drug: Rifapentine (RPT) |
| Arm 2A | Experimental | Participants in Arm 2A will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a boiled egg, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 70, at a dose of 15 mg/kg once daily with a low-fat breakfast. Receives: Drug: Rifapentine (RPT) |
| Arm 2B | Experimental | Participants in Arm 2B will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a low-fat breakfast, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 15 mg/kg once daily with a boiled egg. Receives: Drug: Rifapentine (RPT) |
What is being measured
The primary outcome is the main question the study is designed to answer.
RPT PK parameter: area under the curve over 24 hours (AUC 0 to 24h)
Measured in Group 1, when given at a dose of 20 mg/kg once daily (Arm 1B) and when given at a dose of 10 mg/kg twice daily (Arm 1A)
Measured: Measured at Days 14 and 56
RPT PK parameter: AUC 0 to 24h
Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)
Measured: Measured at Days 14 and 56
Grade 2 or higher signs and symptoms observed while on study beginning with the first dose of study drug and continuing through the follow-up period
Measured: Measured through Day 84
Secondary outcomes (31)
RPT PK parameter: maximum observed plasma concentrations (Cmax)
Measured in Group 1, when RPT is given at a dose of 20 mg/kg once daily (Arm 1B) and at a dose of 10 mg/kg twice daily (Arm 1A)
Measured: Measured at Days 14 and 56
Cmin (trough) values
Measured: Measured at Days 1, 7, 14, 43, 49, 56, 64, and 70
Metabolizer status of human genetic variants/polymorphisms in gene SLCO1B1 and possibly other genes that are thought to affect PK of RIF
Measured: Measured at Day 0
RPT PK parameter: minimum observed plasma concentration (Cmin)
Measured in Group 1, when RPT is given at a dose of 20 mg/kg once daily (Arm 1B) and at a dose of 10 mg/kg twice daily (Arm 1A)
Measured: Measured at Days 14 and 56
RPT PK parameter: oral clearance (CL/F)
Measured in Group 1, when RPT is given at a dose of 20 mg/kg once daily (Arm 1B) and at a dose of 10 mg/kg twice daily (Arm 1A)
Measured: Measured at Days 14 and 56
RPT PK parameter: elimination half-life (T 1/2)
Measured in Group 1, when RPT is given at a dose of 20 mg/kg once daily (Arm 1B) and at a dose of 10 mg/kg twice daily (Arm 1A)
Measured: Measured at Days 14 and 56
RPT metabolite desacetyl-rifapentine (desRPT) PK parameter: AUC 0 to 24h
Measured in Group 1, when RPT is given at a dose of 20 mg/kg once daily (Arm 1B) and at a dose of 10 mg/kg twice daily (Arm 1A)
Measured: Measured at Days 14 and 56
RPT metabolite desRPT PK parameter: Cmax
Measured in Group 1, when RPT is given at a dose of 20 mg/kg once daily (Arm 1B) and at a dose of 10 mg/kg twice daily (Arm 1A)
Measured: Measured at Days 14 and 56
RPT metabolite desRPT PK parameter: Cmin
Measured in Group 1, when RPT is given at a dose of 20 mg/kg once daily (Arm 1B) and at a dose of 10 mg/kg twice daily (Arm 1A)
Measured: Measured at Days 14 and 56
RPT metabolite desRPT PK parameter: CL/F
Measured in Group 1, when RPT is given at a dose of 20 mg/kg once daily (Arm 1B) and at a dose of 10 mg/kg twice daily (Arm 1A)
Measured: Measured at Days 14 and 56
RPT metabolite desRPT PK parameter: T1/2
Measured in Group 1, when RPT is given at a dose of 20 mg/kg once daily (Arm 1B) and at a dose of 10 mg/kg twice daily (Arm 1A)
Measured: Measured at Days 14 and 56
RPT PK parameter: Cmax
Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)
Measured: Measured at Days 14 and 56
RPT PK parameter: Cmin
Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)
Measured: Measured at Days 14 and 56
RPT PK parameter: CL/F
Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)
Measured: Measured at Days 14 and 56
RPT PK parameter: T1/2
Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)
Measured: Measured at Days 14 and 56
RPT metabolite desRPT PK parameter: AUC 0 to 24h
Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)
Measured: Measured at Days 14 and 56
RPT metabolite desRPT PK parameter: Cmax
Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)
Measured: Measured at Days 14 and 56
RPT metabolite desRPT PK parameter: Cmin
Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)
Measured: Measured at Days 14 and 56
RPT metabolite desRPT PK parameter: CL/F
Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)
Measured: Measured at Days 14 and 56
RPT metabolite desRPT PK parameter: T1/2
Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)
Measured: Measured at Days 14 and 56
RPT and its metabolite desRPT PK parameter AUC 0 to 24h at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 )
Measured: Measured at Days 1, 14, 43, 56, and 70
RPT and its metabolite desRPT PK parameter Cmax at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 )
Measured: Measured at Days 1, 14, 43, 56, and 70
RPT and its metabolite desRPT PK parameter Cmin at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 )
Measured: Measured at Days 1, 14, 43, 56, and 70
RPT and its metabolite desRPT PK parameter CL/F at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 )
Measured: Measured at Days 1, 14, 43, 56, and 70
RPT and its metabolite desRPT PK parameter T1/2 at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 )
Measured: Measured at Days 1, 14, 43, 56, and 70
RPT and its metabolite desRPT PK parameter area under the curve extrapolated to infinity (AUC 0 to inf)
Measured: Measured after single dose on Days 1 and 43
RPT and its metabolite desRPT PK parameter CL/F
Measured: Measured after single dose on Days 1 and 43
RPT and its metabolite desRPT PK parameter T1/2
Measured: Measured after single dose on Days 1 and 43
RPT and its metabolite desRPT PK parameter AUC 0 to 24h
Measured: Measured after multiple dose on Days 14 and 56
RPT and its metabolite desRPT PK parameter CL/F
Measured: Measured after multiple dose on Days 14 and 56
RPT and its metabolite desRPT PK parameter T1/2
Measured: Measured after multiple dose on Days 14 and 56
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Apr 2012 (estimated)
- Study startJun 2012
- Primary completionJun 2013
- Study completionJun 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for TuberculosisStudies of the same condition, open and under way.
- More trials run by National Institute of Allergy and Infectious Diseases (NIAID)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 44 participants (actual)
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01574638
- Sponsor's protocol ID
- A5311
- Other IDs
- 11859, ACTG5311, ACTG 5311
- Status last verified
- Oct 2015
- First submitted
- 6 Apr 2012
- Last updated
- 5 Nov 2021
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Zvada SP, Van Der Walt JS, Smith PJ, Fourie PB, Roscigno G, Mitchison D, Simonsson US, McIlleron HM. Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Antimicrob Agents Chemother. 2010 Aug;54(8):3390-4. doi: 10.1128/AAC.00345-10. Epub 2010 Jun 1.
PubMed 20516273Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, Gordin F, Horsburgh CR, Horton J, Khan A, Lahart C, Metchock B, Pachucki C, Stanton L, Vernon A, Villarino ME, Wang YC, Weiner M, Weis S; Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002 Aug 17;360(9332):528-34. doi: 10.1016/s0140-6736(02)09742-8.
PubMed 12241657Dooley KE, Savic RM, Park JG, Cramer Y, Hafner R, Hogg E, Janik J, Marzinke MA, Patterson K, Benson CA, Hovind L, Dorman SE, Haas DW; ACTG A5311 Study Team. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. Antimicrob Agents Chemother. 2015;59(6):3399-405. doi: 10.1128/AAC.05128-14. Epub 2015 Mar 30.
PubMed 25824215
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase I Clinical Trial of the Pharmacokinetics of High-dose Daily Rifapentine, Given as a Single Dose or in Divided Doses to Healthy Volunteers
- ClinicalTrials.gov ID
- NCT01574638
- Acronym / sponsor ID
- A5311
- Conditions
- Tuberculosis
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 44 participants (actual)
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)US National Institutes of Health
- Study start
- Jun 2012
- Primary completion
- Jun 2013 (actual)
- Study completion
- Jun 2013 (actual)
- First posted
- 10 Apr 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate two different ways to give rifapentine (RPT), a drug that may help shorten treatment duration for tuberculosis (TB) disease.
Detailed description
TB continues to be a major global health problem, with an estimated 9.4 million new cases and 1.3 million deaths from TB in 2009. Effective treatment is available, but the current standard therapy consists of 4 different drugs that must be given for 6 months to be effective. RPT is a rifamycin antibiotic approved by the Food and Drug Administration (FDA) to be given twice weekly during the intensive phase of TB treatment and once weekly during the continuation phase of TB treatment. However, studies using this regimen have seen high relapse rates of TB; use of higher and/or more frequent doses may be necessary to attain higher cure rates. This study will evaluate 2 strategies for optimizing RPT exposure: dividing the daily dose in order to increase absorption/overall drug exposure and providing the dose together with food.
Participants will be randomly assigned to one of 4 arms: Arm 1A, Arm 1B, Arm 2A, or Arm 2B. The first 12 participants who indicate that they are willing to remain on the study for up to 12 weeks will be assigned to Arm 2A; all others will be randomized to Arm 1A, 1B, or 2B. Participants in all arms will receive daily RPT from Day 1 to 14, followed by a washout period from Day 15 to 42 during which no RPT will be given, followed by a second period of daily RPT from Day 43 to 56 (and continuing through Day 70 for participants in Arm 2A). Arms 1A and 2B will evaluate twice-daily versus once-daily RPT taken with low-fat meals; Arms 2A and 2B will evaluate once-daily RPT given with an egg versus with a low-fat breakfast.
Total study duration will range from 63 to 70 days for Arms 1A, 1B, and 2B, with 10 study visits: 4 intensive pharmacokinetic (PK) sampling visits (at Days 0 to 2, 13 to 15, 42 to 44, and 55 to 57) and 6 other visits at screening and Days 7, 21, 35, and 49, with the final visit between Days 63 and 70. Total study duration for Arm 2A will range from 77 to 84 days, with 12 study visits: 5 intensive PK sampling visits (over Days 0 to 2, 13 to 15, 42 to 44, 55 to 57, and 69 to 71) and 7 other visits at screening and Days 7, 21, 35, 49, and 64, with the final visit between Days 77 and 84. Intensive PK visits will require the participant to be admitted to the clinic for 1 or 2 nights and to have blood collected multiple times. Interim study visits may consist of giving a medical history, undergoing a physical exam and blood collection, and undergoing a pregnancy test for women of reproductive potential. Participants also will be required to keep a diary of the times they took outpatient study drugs, any medications taken other than the study drug, and any symptoms experienced.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Arm 1B | Experimental | Drug: Rifapentine (RPT)Participants in Arm 1B will receive RPT based on weight at entry, at a dose of 20 mg/kg once daily with a low-fat breakfast, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 10 mg/kg twice daily with low-fat meals. |
| Arm 1A | Experimental | Drug: Rifapentine (RPT)Participants in Arm 1A will receive RPT based on weight at entry, at a dose of 10 mg/kg twice daily with low-fat meals, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 20 mg/kg once daily with a low-fat breakfast. |
| Arm 2A | Experimental | Drug: Rifapentine (RPT)Participants in Arm 2A will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a boiled egg, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 70, at a dose of 15 mg/kg once daily with a low-fat breakfast. |
| Arm 2B | Experimental | Drug: Rifapentine (RPT)Participants in Arm 2B will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a low-fat breakfast, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 15 mg/kg once daily with a boiled egg. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (18 listed)
- Weight of 50 to 100 kg, inclusive
- Absence of HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit within 21 days prior to study entry. NOTE: The term "licensed" refers to a U.S. FDA-approved kit.
- Females of reproductive potential (defined as women who have not been postmenopausal for at least 24 consecutive months, i.e., who have had menses within the preceding 24 months, and do not have documentation of having undergone a sterilization procedure [e.g., hysterectomy or bilateral oophorectomy or salpingectomy]) must have a negative serum or urine beta-human choriogonadotropin (β-HCG) pregnancy test performed within 48 hours prior to entry. The urine test must have a sensitivity of at least 25 mlU/mL and be performed at a laboratory with Clinical Laboratory Improvement Amendment (CLIA) certification or its equivalent.
- Ability and willingness of volunteer to provide written informed consent
- Laboratory values obtained within 21 days prior to entry:
Key exclusion criteria (16 listed)
- Breastfeeding
- Within 30 days prior to entry, use of any prescription medication known to inhibit or induce cytochrome P (CYP)3A metabolizing enzymes (refer to the manufacturers' package inserts for individual drugs). See list posted on the A5311 protocol-specific webpage (PSWP).
- Known intolerance of or allergy to chicken eggs
- Use of rifamycin antibiotics within 60 days prior to entry
- Planned use during the study of prescription medications, herbal supplements, nutritional supplements, or over-the-counter medications except as follows: multivitamins, acetaminophen (up to 650 mg every 6 hours as an analgesic), ibuprofen (up to 600 mg twice daily), naproxen (up to 500 mg twice daily for pain or headache), and Benadryl (diphenhydramine, up to 25 mg daily for insomnia or seasonal allergies) are permitted. The use of topical or locally-acting drugs (e.g., eye drops, IUDs, skin ointments) will be considered on a case-by-case basis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Rifapentine (RPT)Participants will receive 150-mg RPT tablets orally either once or twice daily, with total tablet number/dosage amount varying according to weight at entry and arm assignment and following dosing tables in the protocol. | Drug | Arm 1A, Arm 1B, Arm 2A, Arm 2B |
Primary outcome
RPT PK parameter: area under the curve over 24 hours (AUC 0 to 24h)
Time frame: Measured at Days 14 and 56
Measured in Group 1, when given at a dose of 20 mg/kg once daily (Arm 1B) and when given at a dose of 10 mg/kg twice daily (Arm 1A)
RPT PK parameter: AUC 0 to 24h
Time frame: Measured at Days 14 and 56
Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)
Grade 2 or higher signs and symptoms observed while on study beginning with the first dose of study drug and continuing through the follow-up period
Time frame: Measured through Day 84
31 secondary outcomes
RPT PK parameter: maximum observed plasma concentrations (Cmax)
Time frame: Measured at Days 14 and 56
Cmin (trough) values
Time frame: Measured at Days 1, 7, 14, 43, 49, 56, 64, and 70
Metabolizer status of human genetic variants/polymorphisms in gene SLCO1B1 and possibly other genes that are thought to affect PK of RIF
Time frame: Measured at Day 0
RPT PK parameter: minimum observed plasma concentration (Cmin)
Time frame: Measured at Days 14 and 56
RPT PK parameter: oral clearance (CL/F)
Time frame: Measured at Days 14 and 56
RPT PK parameter: elimination half-life (T 1/2)
Time frame: Measured at Days 14 and 56
RPT metabolite desacetyl-rifapentine (desRPT) PK parameter: AUC 0 to 24h
Time frame: Measured at Days 14 and 56
RPT metabolite desRPT PK parameter: Cmax
Time frame: Measured at Days 14 and 56
RPT metabolite desRPT PK parameter: Cmin
Time frame: Measured at Days 14 and 56
RPT metabolite desRPT PK parameter: CL/F
Time frame: Measured at Days 14 and 56
RPT metabolite desRPT PK parameter: T1/2
Time frame: Measured at Days 14 and 56
RPT PK parameter: Cmax
Time frame: Measured at Days 14 and 56
RPT PK parameter: Cmin
Time frame: Measured at Days 14 and 56
RPT PK parameter: CL/F
Time frame: Measured at Days 14 and 56
RPT PK parameter: T1/2
Time frame: Measured at Days 14 and 56
RPT metabolite desRPT PK parameter: AUC 0 to 24h
Time frame: Measured at Days 14 and 56
RPT metabolite desRPT PK parameter: Cmax
Time frame: Measured at Days 14 and 56
RPT metabolite desRPT PK parameter: Cmin
Time frame: Measured at Days 14 and 56
RPT metabolite desRPT PK parameter: CL/F
Time frame: Measured at Days 14 and 56
RPT metabolite desRPT PK parameter: T1/2
Time frame: Measured at Days 14 and 56
RPT and its metabolite desRPT PK parameter AUC 0 to 24h at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 )
Time frame: Measured at Days 1, 14, 43, 56, and 70
RPT and its metabolite desRPT PK parameter Cmax at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 )
Time frame: Measured at Days 1, 14, 43, 56, and 70
RPT and its metabolite desRPT PK parameter Cmin at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 )
Time frame: Measured at Days 1, 14, 43, 56, and 70
RPT and its metabolite desRPT PK parameter CL/F at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 )
Time frame: Measured at Days 1, 14, 43, 56, and 70
RPT and its metabolite desRPT PK parameter T1/2 at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 )
Time frame: Measured at Days 1, 14, 43, 56, and 70
RPT and its metabolite desRPT PK parameter area under the curve extrapolated to infinity (AUC 0 to inf)
Time frame: Measured after single dose on Days 1 and 43
RPT and its metabolite desRPT PK parameter CL/F
Time frame: Measured after single dose on Days 1 and 43
RPT and its metabolite desRPT PK parameter T1/2
Time frame: Measured after single dose on Days 1 and 43
RPT and its metabolite desRPT PK parameter AUC 0 to 24h
Time frame: Measured after multiple dose on Days 14 and 56
RPT and its metabolite desRPT PK parameter CL/F
Time frame: Measured after multiple dose on Days 14 and 56
RPT and its metabolite desRPT PK parameter T1/2
Time frame: Measured after multiple dose on Days 14 and 56
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2021.
- Background: PubMed 20516273Zvada SP, Van Der Walt JS, Smith PJ, Fourie PB, Roscigno G, Mitchison D, Simonsson US, McIlleron HM. Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Antimicrob Agents Chemother. 2010 Aug;54(8):3390-4. doi: 10.1128/AAC.00345-10. Epub 2010 Jun 1.
- Background: PubMed 12241657Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, Gordin F, Horsburgh CR, Horton J, Khan A, Lahart C, Metchock B, Pachucki C, Stanton L, Vernon A, Villarino ME, Wang YC, Weiner M, Weis S; Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002 Aug 17;360(9332):528-34. doi: 10.1016/s0140-6736(02)09742-8.
- Derived from this study: PubMed 25824215Dooley KE, Savic RM, Park JG, Cramer Y, Hafner R, Hogg E, Janik J, Marzinke MA, Patterson K, Benson CA, Hovind L, Dorman SE, Haas DW; ACTG A5311 Study Team. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. Antimicrob Agents Chemother. 2015;59(6):3399-405. doi: 10.1128/AAC.05128-14. Epub 2015 Mar 30.
Related trials for Tuberculosis
RecruitingPhase 4
Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease
Mycobacterium Avium Complex Pulmonary Disease
RecruitingObservational study
Paradoxical Tuberculosis Reactions in Patients Without HIV Infection
Tuberculosis
Not yet recruitingPhase 2
Re-evaluating the Duration in Children of TB Treatment
Tuberculosis
RecruitingPhase 1/2
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
Tuberculosis
Active, not recruitingPhase 3
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
Tuberculosis, MDR
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Rifapentine (RPT) in people with Tuberculosis, run by National Institute of Allergy and Infectious Diseases (NIAID) at 4 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
RPT PK parameter: area under the curve over 24 hours (AUC 0 to 24h) (time frame: Measured at Days 14 and 56). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01574638, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2021.